Ozempic, Wegovy, Mounjaro: Who Benefits When Obesity is Labeled a Disease?

The Shifting Landscape: Obesity as a Disease

The rapid ascent of GLP-1 receptor agonists, including widely recognized medications like Ozempic, Wegovy, and Mounjaro, has coincided with a concerted effort by pharmaceutical manufacturers to frame obesity not merely as a health risk factor, but as a chronic, progressive disease. Eli Lilly, for instance, has launched campaigns emphasizing that "Obesity is a disease," a sentiment echoed by organizations like the World Health Organization, which describes it as "serious, progressive and chronic." Novo Nordisk, while perhaps more measured in its public pronouncements, is also navigating this evolving medical classification.

This strategic framing is no accident. A medical problem necessitates a medical solution, and a chronic medical condition lays the groundwork for long-term treatment, creating a sustained market for pharmaceutical interventions. The designation of a condition as a "disease" carries significant weight, implying a distinct pathology and a clear target for medical intervention. However, the very definition of "disease" remains a subject of ongoing debate within the scientific and medical communities, particularly for prevalent public health challenges like obesity.

The Medical Case for Obesity as a Disease

The scientific rationale for classifying obesity as a disease is supported by substantial evidence. Epidemiological studies consistently demonstrate a strong correlation between higher Body Mass Index (BMI) thresholds and an increased risk of severe health complications. These include:

• Cardiovascular disease
• Type 2 diabetes
• Stroke
• Premature mortality

Beyond statistical associations, basic and translational research has illuminated a complex web of biological mechanisms contributing to weight gain and hindering weight loss. These include:

• Genetic predispositions
• Disruptions in appetite regulatory pathways
• Neuroendocrine system dysregulation
• Metabolic adaptations that resist weight loss

Yet, the presence of biological mechanisms or associated harm alone does not universally define a condition as a disease. Many conditions with clear biological underpinnings and significant morbidity, such as loneliness, aging, and chronic stress, are not typically classified as diseases. Conversely, conditions like endometriosis or psoriasis, while not always defined by mortality, are recognized as diseases. This highlights that disease classification is often a nuanced judgment, influenced by factors beyond purely scientific observation.

The Institutional and Societal Dimensions of Disease Classification

The decision to classify a condition as a disease is rarely a purely scientific exercise. It is deeply intertwined with institutional, political, and social processes that influence research funding, clinical attention, insurance coverage, and public perception. The American Medical Association's (AMA) deliberations on obesity serve as a prime example of this complex interplay.

In a 2013 report, the AMA Council on Science and Public Health acknowledged the lack of a singular, authoritative definition of disease and the limitations of BMI as a clinical measure. Crucially, the Council also considered the profound institutional implications of designating obesity as a disease, including:

• Reimbursement policies and insurance coverage
• Drug approval processes and prescribing behaviors
• The potential shift from public health initiatives to pharmacological and surgical interventions
• The impact on stigma and public perception

Ultimately, the AMA's decision was not solely based on biological facts but on a careful consideration of the potential consequences of such a classification. This underscores the critical distinction between identifying a medical condition and creating a framework that enables specific interventions and markets.

The Commercial Imperative and GLP-1 Medications

The current discourse surrounding obesity as a disease is inextricably linked to the commercial success of GLP-1 medications. When diagnostic classifications align with significant commercial incentives, there is a risk of blurring the lines between identifying a genuine medical need and creating new markets. The question becomes not just *whether* obesity is a disease, but *who benefits* from this classification, especially now that drugs like Wegovy and Mounjaro are among the most commercially successful pharmaceuticals in history.

It is vital to acknowledge the genuine benefits these medications offer. Semaglutide and related therapies have demonstrated significant cardiovascular advantages, leading to clinically meaningful weight loss and, for many, an improved and extended lifespan. However, a blanket acceptance of the "obesity disease" paradigm without critical examination of its broader implications can narrow our understanding of the problem and its potential solutions.

This narrow focus carries several risks:

1. Clinical Focus on Pharmaceuticals

The disease framework naturally directs resources and attention toward pharmacological interventions, potentially overshadowing behavioral, psychological, and environmental approaches. While these non-pharmacological methods are effective, they are often less patentable. The emphasis on biological solutions, driven by the availability of patent-protected drugs, can bias healthcare choices. Regulatory bodies have already taken action, with fines levied against pharmaceutical companies for campaigns that implied drug treatment was the primary solution to obesity, neglecting alternative management strategies.

2. Political and Environmental Responsibility

Framing obesity as an individual biological issue can absolve broader societal actors from responsibility. If the "problem" lies solely within individual biology, then the "solutions" are also perceived as individual. This can allow the food industry, urban planners, and policymakers to sidestep critical discussions about the environmental and societal factors that contribute to the obesity epidemic, such as food affordability, urban design, and widespread stress.

3. Risk of Long-Term Dependence and Misuse

Evidence suggests that many individuals regain a significant portion of lost weight upon discontinuing GLP-1 medications, creating a strong incentive for long-term or even indefinite treatment. This creates fertile ground for a counterfeit drug market, posing serious risks to consumers. Furthermore, the repurposing of these drugs for purely cosmetic purposes and accelerating abuse amid a problematic diet culture are growing concerns. While GLP-1 drugs generally have a favorable benefit-risk profile when prescribed appropriately, they are not without risks. Common gastrointestinal side effects can lead to discontinuation, and ongoing monitoring is necessary for rarer concerns like gallbladder disease, pancreatitis, aspiration risk, and psychiatric symptoms.

4. Impact on Self-Concept and Stigma

Being told that obesity is a chronic disease requiring medical management fundamentally alters how individuals perceive themselves. For some, this may offer liberation from moral judgment, replacing it with a medical explanation. However, it can also lead to a different form of stigma – judgment for not adhering to treatment, not achieving desired weight loss, or discontinuing medication. While the disease frame may reduce some forms of stigmatization, it can also recast body size as a lifelong medical condition demanding constant monitoring and management.

Lessons from the SSRI Era

The current situation with GLP-1 drugs draws parallels to the widespread adoption of Selective Serotonin Reuptake Inhibitors (SSRIs) in the 1990s. As antidepressants became a cornerstone of psychiatric practice, depression was increasingly reframed as a neurochemical disorder best treated with pharmacotherapy. This framework devalued psychological, social, and economic factors, channeled resources toward drug-based solutions, and led many to understand their suffering through the lens of a "chemical imbalance," a concept whose scientific basis has since been significantly challenged.

Today, despite the continued widespread use of antidepressants, medicine grapples with issues of efficacy, long-term use, withdrawal symptoms, and a growing movement advocating for deprescribing. Depression, however, remains a leading cause of disability globally.

This is not to argue that treating depression as a disease was inherently wrong, nor to definitively state that obesity is not a disease. However, a critical element is often overlooked: in both instances, the designation as a disease has become uncomfortably aligned with commercial interests, potentially stifling crucial discussions about the social, psychological, and economic dimensions of these conditions. For individuals managing their health and weight, tracking progress, doses, and symptoms with tools like Shotlee can provide valuable insights that complement medical guidance.

Conclusion

The classification of obesity as a disease is a complex issue with profound implications. While GLP-1 medications offer significant therapeutic benefits for many, the framing of obesity as a chronic disease by pharmaceutical companies raises important questions about commercial incentives, the narrowing of treatment approaches, and the potential for shifting responsibility away from societal factors. A balanced perspective that acknowledges both the biological realities of obesity and its intricate interplay with social, environmental, and psychological factors is essential for developing comprehensive and equitable solutions.